Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS
a study on Amyotropic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis ALS MN-166 ibudilast Motor Neuron Disease Sclerosis
Lead Scientist at UC Irvine
- Namita Goyal, MD
Health Sciences Professor, Neurology. Authored (or co-authored) 37 research publications.
- accepting new patients
- Start Date
- Completion Date
- This webinar explains the COMBAT-ALS study design and background of MN-166 (ibudilast) as a potential treatment for ALS.
- Phase 2/3
- Study Type
- Last Updated